Amino Acids & Precursors

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Amino Acids & Precursors - References

---

1. Pharmacodynamics & Mechanism of Action

Targeted non-essential and conditionally essential amino acids function as rate-limiting metabolic precursors for redox homeostasis, endothelial vasodilation, mitochondrial translation, and inhibitory neurotransmission.

• GlyNAC & Glutathione (GSH) Synthesis: Intracellular Glutathione ($\gamma$-L-glutamyl-L-cysteinyl-glycine) synthesis is catalyzed sequentially by Glutamate-Cysteine Ligase (GCL) and Glutathione Synthetase (GSS). In aging (>45–60 years), both L-Cysteine (supplied via N-Acetylcysteine / NAC) and Glycine become rate-limiting. Co-administration (GlyNAC) restores the intracellular GSH:GSSG ratio, reverses mitochondrial fatty acid oxidation defects, and lowers oxidative stress (F2-isoprostanes/TBARS).
• Glycine (SCN Thermoregulation & Collagen): Beyond GSH, glycine acts as an inhibitory neurotransmitter at brainstem/spinal strychnine-sensitive GlyR chloride channels, co-agonist at NMDA receptors, peripheral vasodilator via suprachiasmatic nucleus (SCN) NMDA receptors (lowering core body temperature to accelerate slow-wave sleep), and constitutes $33\%$ of all amino acid residues in triple-helix collagen (Gly-X-Y).
• Taurine (2-Aminoethanesulfonic Acid): Conjugates bile acids (taurocholic acid), stabilizes sarcoplasmic reticulum ${\text{Ca}}^{2+}$ handling, forms 5-taurinomethyluridine ($\tau {\text{m}}^5\text{U}$) on mitochondrial ${\text{tRNA}}^{\text{Leu(UUR)}}$ to maintain Electron Transport Chain Complex I translation, and suppresses cellular senescence.
• L-Citrulline (Endothelial NO Precursor): Bypasses hepatic/intestinal arginase-I first-pass extraction, undergoes renal conversion via argininosuccinate synthase/lyase into L-Arginine, and drives Endothelial Nitric Oxide Synthase (eNOS) to generate vasodilatory Nitric Oxide ($\text{NO}$) (synergizing with PDE5 Inhibitors & Endothelial Function).
• Beta-Alanine: Rate-limiting precursor combined with L-histidine via Carnosine Synthase to form intramuscular and cerebral Carnosine ($\beta$-alanyl-L-histidine), an intracellular pH buffer ($\text{p}{K}_a=6.83$) and anti-glycation agent (scavenges reactive carbonyl species and advanced glycation end-products, AGEs).

---

2. Pharmacokinetics & Bioavailability Advantages

Compound	Oral Bioavailability	Primary Pharmacokinetic Advantage
L-Citrulline	$>85\%$ (zero arginase degradation)	Elevates plasma L-arginine AUC $\sim 2\times$ higher than an equivalent oral dose of L-arginine itself
NAC / NACET	$10\text{–}15\%$ (free NAC); $>60\%$ (NACET)	Deacetylated in enterocytes/liver to supply intracellular L-cysteine without systemic cysteine auto-oxidation
Taurine	$\sim 75\text{–}90\%$	Rapid uptake via ${\text{Na}}^{+}/{\text{Cl}}^{-}$-dependent TAUT (SLC6A6) transporter; renal conservation adjusts to dietary load
Glycine	$>90\%$	Crosses BBB passively at gram doses ($3\text{–}5\text{ g}$); clears rapidly ($t_{1/2}\approx 30\text{–}60\text{ min}$)
Beta-Alanine	$>90\%$	Sustained-release matrices blunt peak plasma spikes, preventing MrgprD receptor-mediated paresthesia

---

3. Dosing, Cycling & Synergies

• Standard Protocol:
  • GlyNAC Protocol (for adults $>45$ or high oxidative stress): $3\text{–}5\text{ g/day}$ Glycine + $1,200\text{–}2,400\text{ mg/day}$ NAC (clinical trials used $100\text{ mg/kg/day}$ of each; healthy younger adults can use $3\text{ g}$ Glycine PM + $600\text{–}1,200\text{ mg}$ NAC AM).
  • Taurine: $2,000\text{–}6,000\text{ mg/day}$ divided AM/PM.
  • L-Citrulline (pure base or $2:1$ Malate): $4,000\text{–}6,000\text{ mg}$ ($6\text{–}8\text{ g}$ Citrulline Malate) $45\text{ min}$ pre-training or split daily for blood pressure modulation.
  • Beta-Alanine: $3.2\text{–}6.4\text{ g/day}$ in divided doses ($800\text{–}1,600\text{ mg}$ per dose) to elevate muscle carnosine by $+60\text{–}80\%$ over 4–8 weeks.
• Synergies: Taurine + Beta-Alanine (share the TAUT / SLC6A6 transporter—separate dosing by $\ge 2\text{ hours}$ to prevent competitive inhibition of taurine uptake); L-Citrulline + PDE5 Inhibitors & Endothelial Function ($\text{NO}\to \text{cGMP}$ synergy).
• Contraindications & Biomarkers to Monitor:
  • Precautions: Chronic high-dose NAC immediately post-resistance training can blunt ROS-mediated hormetic hypertrophy signaling (separate by $\ge 4\text{ hours}$ from training); NAC can increase histamine in DAO-deficient individuals; trace molybdenum ($100\text{–}150\mu \text{g}$) supports sulfite oxidase clearance of sulfur amino acids.
  • Biomarkers: RBC Glutathione (GSH:GSSG ratio), GGT (gamma-glutamyl transferase, inverse marker of glutathione sufficiency), Fasting Homocysteine, 8-OHdG / F2-isoprostanes, and Central Blood Pressure.

---

4. Key Scientific Evidence Summary

• GlyNAC Human Aging Trial: Kumar et al. (2023) demonstrated in Journals of Gerontology ($N=36$) that 16 weeks of GlyNAC in older adults restored RBC glutathione by $+164\%$, reduced oxidative stress (TBARS) by $-72\%$, improved mitochondrial fat oxidation by $+78\%$, lowered insulin resistance (HOMA-IR) by $-64\%$, and improved gait speed to match young adult controls.
• Taurine & Lifespan Extension: Singh et al. (2023) published in Science that circulating taurine declines by $>80\%$ in aging humans, monkeys, and mice, and that oral taurine supplementation increased median lifespan in mice by $+10\text{–}12\%$ while improving bone density, muscle strength, and mitochondrial health in non-human primates.
• Citrulline vs. Arginine Pharmacokinetics: Schwedhelm et al. (2008) showed that oral L-citrulline increases plasma L-arginine and cGMP/NO signaling significantly more effectively than oral L-arginine.

See full study breakdowns in Amino Acids & Precursors - References.